Skip to content

Effects of Resistance Training on Substrate Metabolism During the Menstrual Cycle

Acute Effects of Resistance Training on Substrate Metabolism During Different Phases of Menstrual Cycle

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04024826
Enrollment
10
Registered
2019-07-18
Start date
2019-07-01
Completion date
2020-03-16
Last updated
2021-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menstrual Cycle, Substrate Metabolism

Keywords

resistance training, carbohydrate metabolism, fat oxidation

Brief summary

This research project's objective is to investigate substrate metabolism behavior in response to the RT during different phases of the menstrual cycle.

Detailed description

Based on the literature the investigators hypothesize an increase in fat oxidation in early follicular phase(EFP) and late follicular phase (LFP) when compared to early luteal phase (ELP) and late luteal phase (LLP). Given the lack of research in exercise and menstrual cycle - especially in resistance training - results are uncertain unless the investigators base their hypotheses only on the general physiological effects of sex hormones (without exercise). In this case, the investigators expect to see a reduced carbohydrate utilization and an increased utilization of fats in EFP and LFP. In addition, the intervention is focused on muscular endurance and, therefore, it is expected to see a higher reliance on aerobic pathways. It is expected that the effects of the intervention will be added to the effects of estrogens, with increasing fat oxidation when estrogen levels are higher. Lastly, a comparison of fat oxidation levels obtained on each sub-phase would reveal if there are differences in the magnitude of the effect of distinct concentrations of estrogen and progesterone.

Interventions

BEHAVIORALLLP

This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase

BEHAVIORALEFP

This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.

BEHAVIORALLFP

This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.

BEHAVIORALELP

This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase

Sponsors

Southern Illinois University Edwardsville
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

The participants will be randomized into either one of the 4 four phases- namely Early Follicular Phase(EFP-Days1 to 7), Late Follicular Phase(LFP-Days 8 to 14), Early Luteal Phase(ELP-Days 15 to 21) or Late Luteal Phase(LLP-Days 22 to 28) of the menstrual phase. Once the participant is assigned to one of the phases. Each participant will undergo 4 intervention days. the first intervention day will take place during the mid-point of the said phase i.e. EFP- Day 4. After one intervention is complete there will be a washout period and the intervention will take place on the 7th day after the first intervention i.e if the first intervention is LFP done on day 11 of the menstrual cycle the next intervention will take place on day 18 of menstrual cycle which will account for ELP. In this manner, the Participant will be tested in all 4 phases.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Females with BMI-18.5-34.99 and between 18-45 years, with normal menstrual cycle defined as 28-30 days cycles +-3 days. * Including higher BMI participants might alter the results as increased body fat has been linked to changes in different hormonal levels (not only sex hormones) and that might influence substrate utilization. * Sedentary .or physically active for 2 days a week or less.

Exclusion criteria

* • Musculoskeletal injuries, * cardio-respiratory conditions, * metabolic conditions, * irregular menstrual cycle, * menstrual dysfunction or unusual sex hormone levels, * on contraceptives, * on medication that alter hormonal or cardio-respiratory responses, * pre-menopausal symptoms, * on moderate to high-intensity exercise regime more than 2d/week. * All these

Design outcomes

Primary

MeasureTime frameDescription
Changes in Substrate oxidationDuring each exercise session: 1 assessment point on each menstrual cycle phasechanges in substrate oxidation will be measured using cosmed K5 during the intervention phase
Changes in Estrogen levels.At baseline: 1 assessment point on each menstrual cycle phaseBlood would be drawn from the participants for assessment of hormone estrogen
Changes in Progesterone levels.At baseline: 1 assessment point on each menstrual cycle phaseBlood would be drawn from the participants for assessment of hormone Progesterone.

Secondary

MeasureTime frameDescription
Lean Body Mass (kg)At baseline: 1 assessment pointBody composition i.e Fat mass, Lean body mass and Body fat percentage will be measured using dual-energy xray absorptiometry
Muscular strengthAt baseline: 1 assessment pointMuscular strength will be assessed by one-repetition maximum test on leg press and bench press
DietAt baseline: 1 assessment point on each menstrual cycle phaseDiet will be measured using ASA-24h recall
Fat Mass (kg)At baseline: 1 assessment pointBody composition i.e Fat mass, Lean body mass and Body fat percentage will be measured using dual-energy xray absorptiometry
Cardiorespiratory FunctionAt baseline: 1 assessment pointmaximal oxygen consumption will measured on a treadmill with a metabolic cart
Relative Body Fat (%)At baseline: 1 assessment pointBody composition i.e Fat mass, Lean body mass and Body fat percentage will be measured using dual-energy xray absorptiometry

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026